Here are three things to know.
- The drug is approved to treat adults with complicated urinary tract infections, including a type of kidney infection called pyelonephritis.
- Vabomere is an intravenous combination drug made up of meropenem — an antibiotic — and vaborbactam, which inhibits certain resistance mechanisms used by bacteria.
- Rempex Pharmaceuticals’ expects Vabomere to hit the market in the fourth quarter of this year.
More articles on supply chain:
US Bioservices to pay $13.4M to resolve kickback suit
Samsung widens stake in prescription drug market through partnership with Japanese pharmaceutical company
Patients brace for price of ‘breakthrough’ leukemia drug CTL019
